
Nice backs Novartis’ lung cancer drug
pharmafile | May 20, 2016 | News story | | NHS, NICE, Novartis, ceritinib, lung cancer, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) has recommended Novartis’ (VTX: NOVN) Ceritinib (zykadia) as a treatment for lung cancer.
Ceritinib has marketing authorisation in the UK as a treatment for anaplastic lymphoma kinase (ALK) positive advanced non-small-cell lung cancer (NSCLC). Ceritinib is an ALK inhibitor.
The company submission stated that the NHS list price is £4,923.45 for a 30-day supply.
Lung cancer is the third most common cancer in the UK (2013), accounting for 13% of all new cases. It is the second most common cancer in both males (14% of all male cases) and females (12% of all female cases).
In 2013, there were 45,525 new cases of lung cancer in the UK: 24,481 (54%) in males and 21,044 (46%) in females. The crude incidence rate shows that there are 78 new lung cancer cases for every 100,000 males in the UK, and 65 for every 100,000 females.
Anjali Shukla
Related Content

A community-first future: which pathways will get us there?
In the final Gateway to Local Adoption article of 2025, Visions4Health caught up with Julian …

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

The Pharma Files: with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust
Pharmafile chats with Dr Ewen Cameron, Chief Executive of West Suffolk NHS Foundation Trust, about …






